龙红英,马生花

成人隐匿性自身免疫性糖尿病（LADA）是一种起病隐匿的自身免疫性糖尿病，兼具T1DM的免疫学特征和T2DM的临床表现，易被误诊（初诊错误率约5.9%）。我国LADA患者超1000万，居全球首位。其症状与T2DM高度相似，误诊可能导致治疗不当并加速胰岛β细胞衰竭，增加并发症风险。早期胰岛素干预可延缓胰岛功能衰退，降低酮症发生。目前诊疗主要依赖专家共识，缺乏国际权威指南。本文从流行病学、遗传机制、临床特征及治疗策略等方面综述LADA与T2DM的差异，以提升临床识别与管理水平。

成人隐匿性自身免疫性糖尿病；胰岛功能；流行病学；临床特征

[1] Tuomi T,Groop LC,Zimmet PZ,et al.Antibodies to glutamicacid decarboxylase reveal latent autoimmune diabetes mellitusin adults with a non-insulin-dependent onset of disease[J].Diabetes,1993,42(2):359-362. [2] 杨晓玲,索南巴吉,周珂冰,等.2021年成人隐匿性自身免疫性糖尿病共识解读[J].中国实用内科杂志,2022,42(08):647-650. [3] 中国医师协会内分泌代谢科医师分会,国家代谢性疾病临床医学研究中心.成人隐匿性自身免疫糖尿病诊疗中国专家共识(2021版)[J].中华医学杂志,2021,101(38):3077-3091. [4] 张华,陈英剑.成人隐匿性自身免疫糖尿病的研究进展[J].检验医学与临床,2023,20(23):3537-3540. [5] Qiu J,Xiao Z,Zhang Z,Luo S,Zhou Z.Latent autoimmune diabetes in adults in China.Front.Immunol.2022 Aug 25;13:977413. [6] 郭姣姣,刘师伟.成人隐匿性自身免疫性糖尿病的生物学标志物研究进展[J].新医学,2024,55(06):474-479. [7] Zhou Z,Xiang Y,Ji L,et al.Frequency,immunogenetics,and clinical characteristics of latent autoimmune diabetes in China(LADA China study)a nationwide,multicenter,clinic based cross-sectional study[J].Diabetes,2013,62(2):543-550. [8] Hu J,Zhang R,Zou H,Xie L,Zhou Z,Xiao Y.Latent Autoimmune Diabetes in Adults(LADA):From Immunopathogenesis to Immuno- therapy.Front.Endocrinol.2022;13:917169.Published 2022 Jul 21. [9] Huang G,Yin M,Xiang Y,et al.Persistence of glutamic acid decarboxylase antibody(GADA)is associated with clinical characteristics of latent autoimmune diabetes in adults:a prospective study with 3-year follow-up.Diabetes Metab Res Rev.2016;32(6):615-622. [10] Andersen MK.New Insights into the Genetics of Latent Autoimmune Diabetes in Adults.Curr Diab Rep.2020;20(9):43.Published 2020 Jul 28. [11] Isomaa B,Almgren P,Henricsson M et al(1999)Chronic complications in patients with slowly progressing autoimmune type 1 diabetes(LADA).Diabetes Care 22:1347–1353. [12] Baum P,Hermann W,Verlohren HJ,Wagner A,Lohmann T,Grahmann F(2003)Diabetic neuropathy in patients with‘latent autoimmune diabetes of the adults’(LADA)compared with patients with type 1 and type 2 diabetes.J Neurol 250:682–687. [13] The Diabetes Control and Complications Trial Research Group(1998)Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial.A randomized,controlled trial.Ann Intern Med 128:517–523. [14] Ridker PM(2003)High-sensitivity C-reactive protein and cardiovascular risk:rationale for screening and primary prevention.Am J Cardiol 92:17K–22K. [15] UK Prospective Diabetes Study(UKPDS)Group(1998)Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34).Lancet 352:854–865. [16] 田婷,余江毅,孙心怡,等.成人隐匿性自身免疫性糖尿病的临床特点及其甲状腺自身免疫特征[J].广西医学,2021,43(24):2893-2896. [17] 李香淑.成人隐匿性自身免疫性糖尿病与2型糖尿病临床特点分析[D].延边大学,2022. [18] 姜姗姗.成人隐匿性自身免疫性糖尿病患者临床特征的分析[D].大理大学,2020. [19] 顾燕,于瑞萍,罗建华,等.成人隐匿性自身免疫糖尿病的临床特征分析[J].实用糖尿病杂志,2015,11(02):36-38. [20] 薛春萍,刘传江,汪闯,等.成人隐匿性自身免疫性糖尿病与2型糖尿病的检验指标差异分析[J].糖尿病新世界,2023,26(11):56-59. [21] Poudel RR.Latent autoimmune diabetes of adults:From oral hypoglycemic agents to early insulin.Indian J Endocrinol Metab.2012;16 Suppl 1(Suppl1):S41-S46. [22] Zhou Z,Xu M,Xiong P,Yuan J,Zheng D,Piao S.Prognosis and outcome of latent autoimmune diabetes in adults:T1DM or T2DM?.Diabetol Metab Syndr.2024;16(1):242.Published 2024 Oct 7. [23] Zhang Z,Yan X,Wu C,Pei X,Li X,Wang X,et al.Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protectβ-cell function in LADA patients:A 1-year pilot study.Diabetes/metabolism Res Rev(2020)36(5):e3298. [24] Yin W,Luo S,Xiao Z,Zhang Z,Liu B,Zhou Z.Latent autoimmune diabetes in adults:a focus onβ-cell protection and therapy. Front.Endocrinol.2022;13:959011.Published 2022 Aug 5. [25] Zelniker TA,Wiviott SD,Raz I,Im K,Goodrich EL,Bonaca MP,et al.SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes:A systematic review and meta-analysis of cardiovascular outcome trials.Lancet (2019)393(10166):31–9. [26] Agardh CD,Cilio CM,Lethagen A,Lynch K,Leslie RD,Palmér M,et al.Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes.J Diabetes its complications(2005)19(4):238-46.

点击下载PDF